Phathom Pharmaceuticals logo
Phathom Pharmaceuticals
PHAT | NASDAQ
Chart Builder DCF Calculator
$5.88
-$0.18 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$5.88
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Phathom Pharmaceuticals Company Profile

Company profile explained

Company Profile

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Key Executives

Name Position
Steven L. Basta Chief Executive Officer, President & Director
Anne Marie Cook Chief Legal Officer & Corporate Secretary
Bill Aprea Senior Vice President, Chief Compliance Officer & Deputy Chief Legal Officer
Paul Cocja Chief People Officer
Azmi Nabulsi Co-Founder
David A. Socks Co-Founder
Eric Sciorilli Director of Business Development & Investor Relations
Jonathan Bentley Senior Vice President and Head of Sales, Operations & Training
Nancy R. Phelan Senior Vice President of Marketing & Analytics
Robert Breedlove Vice President of Finance & Principal Accounting Officer
Sanjeev Narula Chief Financial & Business Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 10-Q Quarterly Report
Oct 29, 2026 8-K Current Report
Oct 26, 2026 8-K Current Report
Oct 23, 2026 8-K Current Report
Oct 08, 2026 4 Filing
Sep 29, 2026 8-K Current Report
Sep 08, 2026 4 Filing
Jul 30, 2026 10-Q Quarterly Report
Jul 30, 2026 8-K Current Report
Jul 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Phathom Pharmaceuticals
Phathom Pharmaceuticals logo
Country United States
IPO Date Oct 25, 2019
Industry Biotechnology
Sector Healthcare
Employees 371
CEO Steven L. Basta

Contact Details

100 Campus Drive Florham Park, New Jersey 07932 United States

Stock Details

Ticker Symbol PHAT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001783183
CUSIP Number 71722W107
ISIN Number US71722W1071
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.